- Home
- SOL vs ACOG Comparison
SOL vs ACOG Comparison
Compare SOL & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ACOG
- Stock Information
- Founded
- SOL 2005
- ACOG 2000
- Country
- SOL United States
- ACOG Canada
- Employees
- SOL N/A
- ACOG N/A
- Industry
- SOL Semiconductors
- ACOG
- Sector
- SOL Technology
- ACOG
- Exchange
- SOL Nasdaq
- ACOG Nasdaq
- Market Cap
- SOL 84.6M
- ACOG 91.6M
- IPO Year
- SOL 2008
- ACOG N/A
- Fundamental
- Price
- SOL $1.26
- ACOG $4.12
- Analyst Decision
- SOL Buy
- ACOG Strong Buy
- Analyst Count
- SOL 3
- ACOG 1
- Target Price
- SOL $3.50
- ACOG $20.00
- AVG Volume (30 Days)
- SOL 218.6K
- ACOG 75.4K
- Earning Date
- SOL 05-22-2025
- ACOG 05-20-2025
- Dividend Yield
- SOL N/A
- ACOG N/A
- EPS Growth
- SOL N/A
- ACOG N/A
- EPS
- SOL N/A
- ACOG N/A
- Revenue
- SOL $92,067,000.00
- ACOG N/A
- Revenue This Year
- SOL N/A
- ACOG N/A
- Revenue Next Year
- SOL $45.37
- ACOG N/A
- P/E Ratio
- SOL N/A
- ACOG N/A
- Revenue Growth
- SOL N/A
- ACOG N/A
- 52 Week Low
- SOL $1.04
- ACOG $3.75
- 52 Week High
- SOL $3.00
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- SOL 38.04
- ACOG N/A
- Support Level
- SOL $1.16
- ACOG N/A
- Resistance Level
- SOL $1.46
- ACOG N/A
- Average True Range (ATR)
- SOL 0.11
- ACOG 0.00
- MACD
- SOL -0.03
- ACOG 0.00
- Stochastic Oscillator
- SOL 20.00
- ACOG 0.00
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.